FDA Approves New Obesity Drug, Tirzepatide, for Wider Use
The FDA has approved a new obesity drug called tirzepatide, which will compete with the popular drug Wegovy. Tirzepatide, sold under the name Zepbound, has been shown to help patients lose an average of 18% of their body weight in drug trials, compared to the 15% weight loss seen with Wegovy. This new medication joins a class of drugs that are transforming weight loss and obesity treatment. Obesity is a condition that affects millions of American adults and is linked to various diseases. Tirzepatide is already approved for diabetes treatment under the name Mounjaro, and this approval addresses the unmet medical need for safe and effective weight loss options for people with obesity.
- F.D.A. Approves New Obesity Drug That Will Compete With Wegovy The New York Times
- FDA approves Eli Lilly’s diabetes drug Mounjaro for obesity under new name, Zepbound CNN
- FDA approves Mounjaro for weight loss FOX 32 Chicago
- FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug CNBC
Reading Insights
0
20
1 min
vs 3 min read
73%
412 → 113 words
Want the full story? Read the original article
Read on The New York Times